Tagged with

Zambon You declared in a recent interview that Zambon Group will always keep complying with the vision of your father Alberto, who has always refused acquisition offers from multinationals- a striking approach, in a context of pharmaceutical clusters when so many Italian players have been swallowed by wider structures. Which specific…

CROM You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and also have 12 years of experience in all aspects of drug development in a major international pharmaceutical company. What aspect…

Ferlito Ferlito Farmaceutici was established in 1937 and has since then grown to become one of the most renowned pharmaceutical pre-wholesalers in Italy. Which specific values of Ferlito do you think were key to success and enabled the company to get where it is today, keeping growing organically and remaining independent?…

Italfarmaco Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to success that enabled the company not to fail like others and get where it is today, keeping growing organically yet…

Chungcheongbuk-do Although Chungcheongbuk-do is a small province in terms of territory and population, it has gained increasing importance in Korea’s economy. What are the main drivers of this growing economic progression? Chungbcheongbuk-do (Chungbuk) was traditionally an agriculture-based province until its economy started to shift towards more knowledge intensive activities in the…

Abiogen You created Abiogen in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition, keeping building on the legacy of your great-grandfather Commendatore Alfredo Gentili, combining it with your personal innovative vision to create a “new reality”. To have a better understanding of…

CANIFARMA This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be interviewing you as General Director of CANIFARMA with over 30 years of experience in the industry. There have been a…

CANIFARMA There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has also grown in power since it was started 10 years ago. What has struck you as the most impactful change…

Menarini After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life, I worked three shifts. Meaning arriving at the office at 8:30am, come back home at 1pm, back to work at…

Korea Pharmaceutical Manufacturers Associatio Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of pharmaceutical companies, and therefore plays a pivotal role in advancing the industry in the country. We encourage and support our…

ADM Korea How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting to produce bimolecular products, specifically they were working on vaccines. CJ needed personnel with expertise in this area and I…

LG Life Sciences LG Life Sciences seems quite unique among the rest of pharmaceutical companies in Korea which tend to be family owned. How has this set LGLS apart in terms of its development and strategy in the industry? Traditionally, companies in Korea have focused on generic drugs and in-licensing new medicines, so…